Five-year experience in the ruzam complex clinical therapy for patients with the bronchial asthma

Abstract

A retrospective study of clinical therapy with the antiallergic medicine RUZAM is described. The medicine is a nonspecific immunity stimulator which is a product of a staphylococcus vital activity. RUZAM is allowed for use in Russia. It is efficient for the bronchial asthma complex therapy of mainly the mild and moderate disease course. The RUZAM treatment has made it possible to reduce the medicine therapy annual volume for the main medicine groups including: by 37.9% for sympathomimatics, by 7.4% for Intal, by 26.4% for short-action theophylline, by 8.4% for prolonged-action theophylline and by 4.2% for inhaled corticosteroids. The money saving is significant for the drug therapy. The cost of annual drug therapy for a patient was 599,400 rubles. This figure is for a group of 95 patients treated with RUZAM. The test group included 40 patients. The cost of their treatment was 1,002,900 rubles what was 1.7 times larger.